Coronary risk factors in patients in secondary prevention: a report of the CENARE/INCIENSA Cardiac Rehabilitation Program
DOI:
https://doi.org/10.51481/amc.v40i1.580Keywords:
Enfermedad coronaria, Factores de riesgo, prevención enfermedad coronariaAbstract
Coronary heart disease is the leading cause of death in Costa Rica and the prevalence is increasing. An analysis of the main clinical characteristics and mayor coronary risk factors of patients with coronary atherosclerosis including survivors of myocardial infarction or revascularization procedures who were attended at the Cardiac Rehabilitation Clinic (CENARE e INCIENSA) during 1993 to 1996 is presented here. Mayor coronary risk factors were history of smoking, dyslipidemia, type 2 diabetes mellitus and systemic hypertension. The lipid profile showed that 80 per cent of the patients had LDL cholesterol concentrations above 100 mg/dl. Recommendations are made to establish country wide programs to unify treatment criteria to modify coronary risk factors, in particular, the abnormal lipid profile, common in such patients, aimed to reduce subsequent coronary events.
Downloads
References
Bridging the gap: science and policy in action. Declaration of the advisory board. Victria, Canada, 1992. May 28.
Castelli W P. Epidemiology Of coronary heart disease: The Framinghan study. Ann Inter Med (2A): 4-12,
Multiple risk factor intervention trial research group. Multiple risk factor intervention trial. Risk factor changes and mortality results.JAMA
Pasternak R C. Gundy S M, Levy D, Thompson. Task Force 3. Spectrum of risk factors for coronary heart disease. JACC 1996; 27:978-990. 5. Lipid Research Clinics coronary primary prevention trial results I. Reduction in incidence of CHD. Lipid Research Clinics Program. JAMA 1984251 1351-64
Frick MH. Elo O. Haapa K, Heinonen OP, Heinsalmi P. Helo P et al. Helsinki Heart Study: Primary-prevention trial With Gemfibrozil in middle-aged Inen with dyslipidemia. N Engl J Med. 1237-45
Brown G, Albers J J. Fisher L. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels Of apolipoprotein B. N J Med 1990:323: 1289-98.
The Scandinavian Simvastatin Survival Study Group. Ramdomised trial Of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994:344: 1383-1389.
Summary of the second report Of the management cholesterol education program (NECP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel Il) JAMA 1993: 269: 301523.
Hjerman, l. Primary prevention Of coronay heart disease. Acta Med Scan 1985; 218:1-4.
Jiménez Montero JG. La Promoci6n de la salad: un instrulnento para prevenir las enfermedades cardiovasculares. Rev Cent Adm Publica.
Departamento de Estadistica de la Caja Costarricense de Seguro Social. 1993.
Rosellö M. Bolanos M. Aráuz AG. Rehabilitaciön cardiaca: Un ario después. 1996 Memorias Lll Congreso Médico Nacional, San José. Costa Rica.
Lipid and lipoprotein analysis, Lipid Research Clinics Program Manual Of laboratory operations. vol l. Washington DC. U.S. Govermnent priting office. 1974: (DHEW' publication no. NIH) 75-628.
Friedwald WT. Levy RL. Fridrikson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma. without use of the preparative ultracentrifugation. Clin Chem. 1972; 18: 499-02
Jiménez Montero JG. ()flz Carazo. Vargas Picado MA. Jimenez Z. Aráuz Hernandez AG, Aguilar Peralta A, Mora Morales E. Dislipoproteinetnias y cardiopatia isquémica prematura. Hallazgos en 29 casos. Rev Cost Cien Med 1988: I
Barrett-Connor E. Bush T L. Oestrogen and coronary heart disease in women. JAMA 1991: 265:1861-67.
nskinen MR. Diabetic dyslipidemia in NIDDM
Pyorala K. Pedersen TR. Kjeshus. Faergeman O, Olson AG, Thorgeirsson G. Cholesterol lowering with sirnvastatin improves prognosis Of diabetic patientss with coronary heart disease. Diabetes Care 1997: 20 620.
Miller GJ, Miller NE, Plasma high-density-lipoprotein concentration and development of ischemic heart-disease. Lancet 1975; l: 16-9.
Abbott RD. Wilson PW'F, Kannel WB, Qustelli wp High density lipoprotein cholesterol. total cholesterol and myocardial infarction: The Framingham Study. Arteriosclerosis 1988; 8:207-1 1.
NIH Consensus Conference. Trigliceride, high-densisty lipoprotein and coronary heart disease. JAMA 1993; 269:505-510
Jlrnénez Montero J G, Vinocour, M. , Torlös, J, Letchrnann, M, Piedra, M. Guia práctica para la valoraciön y tratamiento de IOS pacientes con dislipoproteinemias con enfermedad vascular o sin ella. 1996.
Jiménez Montero JG, Vargas Picado, MA, Aráuz Hernández AG. Effect of a lipid lowering diet on serum lipid and lipoprotein concentrations in hypercholesterolemic females. Cardiologia Internacontinental. 1997; 6:3-8.
Witztum J L Drugs used in the treatment of hyperlipoproteinemies. En: Goodman & Gilman's The pharmacologic basis of therapeutics. MC Graw Hill, Ninth Ed 1996; 875-897.
Smith S, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto A, et al. AHA Consensus panel statement preventing heart attack and death in patients with coronay diseases. JACC 1995;26
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
